Chronic Obstructive Pulmonary Disease

Last updated 1 Jun 2026 · Respiratory

📋 Key Information Summary

📋

COPD is diagnosed when a patient aged ≥40 years presents with chronic respiratory symptoms (dyspnoea, chronic cough, sputum production) and a post-bronchodilator FEV₁/FVC ratio < 0.70 on spirometry — spirometry is essential and must not be omitted.
GOLD 2024 spirometric staging: GOLD 1 (FEV₁ ≥ 80% predicted), GOLD 2 (50–79%), GOLD 3 (30–49%), GOLD 4 (< 30%). The updated ABE grouping (2023+) replaces ABCD: Group A (0–1 exacerbations, no hospitalisation, mMRC 0–1), Group B (0–1 exacerbations, no hospitalisation, mMRC ≥ 2), Group E (≥ 2 moderate exacerbations or ≥ 1 hospitalisation).
SMOKES Checklist — Screen all patients, Motivate quit attempts, Offer pharmacotherapy, Know triggers and withdrawal, Encourage support services (Quitline 13 7848), Schedule follow-up within 1–2 weeks of quit date.
First-line pharmacotherapy for smoking cessation: varenicline (Champix®) or combination NRT (patch + lozenge/gum); bupropion (Zyban®) is second-line. All are PBS-listed with authority required.
Initial bronchodilator therapy depends on GOLD ABE group: Group A — a short-acting bronchodilator PRN (SABA or SAMA); Group B — a LAMA or LABA; Group E — a LAMA, or LAMA + LABA if eosinophils ≥ 300 cells/µL consider LAMA + LABA + ICS.
Long-acting muscarinic antagonists (LAMA): tiotropium (Spiriva®) 18 µg OD via HandiHaler or 2.5 µg OD via Respimat — first-line for most patients. PBS Authority Required.
Long-acting beta₂-agonists (LABA): salmeterol (Serevent®) 50 µg BD or formoterol (Oxis® / Symbicort® component) 12 µg BD. PBS Authority Required.
Inhaled corticosteroids (ICS) should NOT be used as monotherapy in COPD. Add ICS (e.g., fluticasone furoate or budesonide) when blood eosinophils ≥ 300 cells/µL on ≥ 2 moderate exacerbations/year, or eosinophils 100–300 with ≥ 1 hospitalisation. Risk of pneumonia — reassess and withdraw if no benefit after 3–6 months.
Long-term oxygen therapy (LTOT) is indicated when PaO₂ ≤ 55 mmHg (or SpO₂ ≤ 88%), or PaO₂ 56–59 mmHg with cor pulmonale, polycythaemia (Hct > 55%), or pulmonary hypertension — prescribed ≥ 15 h/day including overnight; funded via State/Territory schemes and Home Oxygen Programs.
Pulmonary rehabilitation is a cornerstone of COPD management and should be offered to ALL symptomatic patients (GOLD B/E). Programmes are 6–8 weeks (2–3 sessions/week), include exercise training, education, and psychosocial support; available through public hospital outpatient programmes and some private providers with MBS item 93660 where eligible.
Acute exacerbations: short course of oral prednisolone 40–50 mg daily for 5 days + short-acting bronchodilators + antibiotics (amoxicillin or doxycycline) if increased sputum purulence or volume — aim to manage in community where possible.
Aboriginal and Torres Strait Islander Australians have 2.5× the COPD burden and earlier onset; proactive spirometry screening, culturally safe smoking cessation, and spirometry in remote/regional clinics with telehealth support are critical to closing the gap.

Introduction & Australian Epidemiology

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterised by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases. COPD encompasses chronic bronchitis and emphysema and is distinguished from asthma by its largely irreversible airflow obstruction, though overlap exists (asthma–COPD overlap, ACO).

In Australia, COPD is the fifth leading cause of death and the fourth leading cause of disease burden in adults aged ≥ 45 years. The Australian Institute of Health and Welfare (AIHW) estimates that approximately 638,000 Australians (2.6% of the population) live with COPD, though the true prevalence is likely higher due to under-diagnosis. COPD accounts for over 73,000 hospitalisations annually and approximately 7,700 deaths per year. The annual economic cost exceeds .8 billion.

COPD disproportionately affects Aboriginal and Torres Strait Islander Australians, people of lower socioeconomic status, and those in rural and remote areas. Smoking remains the leading modifiable risk factor, responsible for approximately 70–80% of COPD cases. Other important exposures include occupational dusts, biomass fuel smoke (particularly relevant in some ATSI and migrant communities), ambient air pollution, and alpha-1 antitrypsin deficiency (approximately 1–2% of Australian COPD cases).

Diagnosis and management of COPD in general practice requires spirometric confirmation, a structured approach to pharmacotherapy based on the GOLD ABE framework, proactive smoking cessation support, and timely referral for pulmonary rehabilitation and long-term oxygen therapy when indicated. This article provides an evidence-based Australian framework aligned with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 Report, Thoracic Society of Australia and New Zealand (TSANZ) guidelines, and Australian Therapeutic Guidelines (eTG).

⚠️

Spirometry is essential. COPD should not be diagnosed on clinical history alone. Post-bronchodilator spirometry (FEV₁/FVC < 0.70) must be confirmed before initiating long-term pharmacotherapy. Spirometry services are available through community-based respiratory clinics, lung function laboratories (MBS item 12203), and increasingly via practice nurse-led models.

Diagnosis & Staging of COPD

Clinical Suspicion

Consider COPD in any adult aged ≥ 40 years presenting with one or more of the following:

Exertional dyspnoea that is persistent and progressive
Chronic cough (productive or non-productive)
Regular sputum production
Recurrent lower respiratory tract infections
History of exposure to risk factors: tobacco smoke, occupational dusts, biomass fuel, indoor/outdoor air pollution

Spirometric Diagnosis

A diagnosis of COPD is confirmed by post-bronchodilator spirometry demonstrating a fixed airflow obstruction:

FEV₁/FVC ratio < 0.70 after administration of 400 µg salbutamol (or 160 µg ipratropium) via MDI + spacer
Spirometry should be performed by trained operators using ATS/ERS quality standards
MBS item 12203 — Medicare rebate for spirometry performed under medical supervision

🚨

Do not over-diagnose COPD in the elderly. In patients aged > 65 years, a fixed ratio < 0.70 may reflect normal age-related decline rather than true COPD. Consider using the lower limit of normal (LLN) for FEV₁/FVC where available, and correlate with clinical context (symptoms, exposure history, imaging). Misdiagnosis leads to unnecessary long-term medication use.

GOLD Spirometric Severity Staging

GOLD Stage	Severity	Post-BD FEV₁ (% predicted)
GOLD 1	Mild	FEV₁ ≥ 80%
GOLD 2	Moderate	50% ≤ FEV₁ < 80%
GOLD 3	Severe	30% ≤ FEV₁ < 50%
GOLD 4	Very Severe	FEV₁ < 30%

GOLD ABE Classification (2023+ Update)

The GOLD 2024 report updated the classification system. The former ABCD tool has been replaced by the ABE grouping, which combines symptom burden (mMRC dyspnoea scale or CAT score) with exacerbation history to guide initial pharmacotherapy.

Group	Exacerbations (prior year)	Symptoms	Key Features
Group A	0–1 moderate; none hospitalised	mMRC 0–1 or CAT < 10	Low symptoms, low exacerbation risk
Group B	0–1 moderate; none hospitalised	mMRC ≥ 2 or CAT ≥ 10	More symptoms, low exacerbation risk
Group E	≥ 2 moderate OR ≥ 1 hospitalised	Any symptom level	Exacerbation-prone (combines former C + D)

Differential Diagnosis

Important differentials to consider before confirming COPD:

Asthma: typically reversible airflow obstruction, onset < 40 years, variable symptoms, atopic history
Heart failure: orthopnoea, PND, bilateral crackles, raised BNP/NT-proBNP
Non-tuberculous mycobacteria (NTM): especially in elderly women with bronchiectasis
Alpha-1 antitrypsin deficiency: consider in patients < 45 years, non-smokers, lower lobe emphysema, family history — request serum alpha-1 antitrypsin level and phenotyping
Interstitial lung disease: restrictive pattern on spirometry, typical HRCT findings
Obstructive sleep apnoea / obesity hypoventilation syndrome

Investigations at Diagnosis

Essential Post-bronchodilator spirometry Confirms diagnosis; FEV₁/FVC < 0.70. MBS 12203.

Essential Chest X-ray (PA + lateral) Excludes lung cancer, pneumonia, heart failure; may show hyperinflation. MBS 58506.

Available Full blood count Polycythaemia (chronic hypoxia), eosinophilia (ICS decision aid), anaemia. MBS 65070.

Available Arterial blood gas If SpO₂ ≤ 92% or clinical features of Type 2 respiratory failure — guides oxygen therapy decisions.

Available Alpha-1 antitrypsin level Consider in all patients < 45 years; phenotyping if level low. MBS 65695.

Available CT chest (HRCT) If suspecting bronchiectasis, lung cancer screening, or emphysema subtyping. MBS 56301. Usually via respiratory specialist.

Available Echocardiography If clinical suspicion of pulmonary hypertension or cor pulmonale. MBS 55114.

SMOKES Checklist & Smoking Cessation

Smoking cessation is the single most effective intervention to slow the rate of FEV₁ decline in COPD and improve survival. Every COPD consultation is an opportunity for smoking cessation support. The SMOKES framework (adapted for Australian general practice) provides a structured, evidence-based approach.

The SMOKES Checklist

Screen All Patients

Ask about smoking status at every visit. Document in the patient health record. Use the 5As: Ask, Assess, Advise, Assist, Arrange.

Motivate Quit Attempts

Use motivational interviewing. Emphasise personal benefits: slowing FEV₁ decline, reduced exacerbations, improved quality of life. For COPD patients, quitting at GOLD 1–2 can add years of life.

Offer Pharmacotherapy

Varenicline (first-line), combination NRT, or bupropion. Offer to all patients making a quit attempt unless contraindicated. Prescribe before the quit date.

Know Triggers & Withdrawal

Identify smoking triggers (stress, alcohol, coffee, social settings). Prepare the patient for withdrawal symptoms (irritability, craving, insomnia, weight gain) and develop coping strategies.

Encourage Support Services

Refer to Quitline (13 7848), QuitCoach (quitnow.gov.au), Aboriginal Quitline (13 7848 then press 1), digital support apps, and local community health services.

Schedule Follow-Up

Review within 1–2 weeks of quit date. Reinforce success, manage relapse non-judgementally. Continue follow-up for at least 3 months. MBS items for smoking cessation support (MBS 710, 712, 715 via GPMP/TCA).

Pharmacotherapy for Smoking Cessation

💊

Varenicline

Champix® · Partial nicotinic receptor agonist

Adult dose 0.5 mg PO OD for days 1–3, then 0.5 mg PO BD for days 4–7, then 1 mg PO BD for 11 weeks (total 12-week course). May repeat once.

Start 1–2 weeks before quit date

Renal adjustment eGFR < 30: max 1 mg OD (0.5 mg BD) — reduce to 0.5 mg OD if not tolerated

Hepatic adjustment No adjustment required

PBS status ⚑ PBS Authority Required Two courses per 12 months

💊

Nicotine Replacement Therapy (combination)

Nicabate® / Nicorette® / Habitrol® · Nicotinic receptor agonist

Adult dose — patch 21 mg/24h patch (heavy smokers ≥ 10 cigs/day) or 14 mg patch (lighter smokers). Apply OD, rotate sites. 8–12 weeks.

Adult dose — breakthrough Nicotine lozenge 2 mg or 4 mg (1 piece 1–2 hourly PRN), or nicotine gum 2 mg or 4 mg PRN, or nicotine inhalator 10 mg cartridge PRN

Renal adjustment No adjustment required

PBS status ✔ PBS General Benefit (patches); ✘ Not PBS (gum, lozenge, inhalator — OTC)

💊

Bupropion

Zyban® · Noradrenaline/dopamine reuptake inhibitor

Adult dose 150 mg PO OD for 6 days, then 150 mg PO BD for 7–9 weeks (total 7–12-week course)

Start 1–2 weeks before quit date

Renal adjustment 150 mg OD if eGFR < 30 or on dialysis

Cautions Contraindicated with seizure history, eating disorders, abrupt alcohol/benzo withdrawal. Avoid MAOIs.

PBS status ⚑ PBS Authority Required

✅

Combination NRT is more effective than monotherapy. A nicotine patch (baseline steady-state delivery) plus a short-acting form (lozenge, gum, or inhalator for breakthrough cravings) approximately doubles quit rates compared to single NRT. Encourage patients to use both forms simultaneously.

Behavioural Support

Pharmacotherapy is most effective when combined with behavioural support. In Australia:

Quitline 13 7848: free telephone counselling, callback services, interpreter support available
QuitCoach & My QuitBuddy: online and app-based tools (quitnow.gov.au)
Aboriginal and Torres Strait Islander-specific services: Aboriginal Quitline (press 1), Tackling Indigenous Smoking (TIS) programme workers in ACCHOs
GP Practice Incentives: PIP quality improvement measures include smoking status recording and cessation support

Bronchodilators (SABA, LAMA, LABA) & Inhaled Corticosteroids

Pharmacotherapy Principles

Bronchodilators are the mainstay of COPD pharmacotherapy. They do not modify long-term disease progression but reduce symptoms, improve exercise tolerance, and reduce exacerbation frequency. Therapy should be individualised using the GOLD ABE framework, with escalation and de-escalation based on response. Correct inhaler technique is critical and should be checked at every visit.

⚠️

Inhaler technique is paramount. Up to 80% of Australian COPD patients use their inhalers incorrectly. Use the three-step teach-back method: (1) demonstrate, (2) patient returns demonstration, (3) confirm competence. Consider device selection (pMDI + spacer vs DPI vs SMI) based on patient inspiratory flow and dexterity. Check technique at every visit.

Initial Pharmacotherapy by GOLD ABE Group

GOLD Group	First-Line	Consider Escalation
Group A	SABA or SAMA PRN	If persistent symptoms → LAMA or LABA
Group B	LAMA or LABA	Persistent symptoms → LAMA + LABA
Group E	LAMA + LABA	If eosinophils ≥ 300 cells/µL → LAMA + LABA + ICS

Short-Acting Bronchodilators (SABA & SAMA)

💨

Salbutamol

Ventolin® / Asmol® · SABA

Adult dose 100–200 µg (1–2 puffs) via pMDI + spacer PRN; nebuliser 2.5–5 mg PRN in acute settings

Onset 3–5 minutes; duration 4–6 hours

PBS status ✔ PBS General Benefit

💨

Ipratropium

Atrovent® · SAMA

Adult dose 40 µg (2 puffs) via pMDI + spacer PRN or QID; nebuliser 250–500 µg QID

Onset 15–30 minutes; duration 6–8 hours

PBS status ✔ PBS General Benefit

Long-Acting Muscarinic Antagonists (LAMA)

💊

Tiotropium

Spiriva® HandiHaler® / Respimat® · LAMA

Adult dose (HandiHaler) 18 µg inhaled OD via capsule DPI

Adult dose (Respimat) 2.5 µg (2 puffs) OD via soft mist inhaler

Renal adjustment No adjustment required (avoid if eGFR < 10 — limited data)

PBS status ⚑ PBS Authority Required (COPD with documented airflow obstruction)

💊

Umeclidinium

Incruse® Ellipta® · LAMA

Adult dose 62.5 µg inhaled OD via Ellipta DPI

PBS status ⚑ PBS Authority Required

💊

Glycopyrronium

Seebri® Breezhaler® · LAMA

Adult dose 50 µg inhaled OD via capsule DPI

PBS status ⚑ PBS Authority Required

Long-Acting Beta₂-Agonists (LABA)

💊

Salmeterol

Serevent® Diskus® · LABA

Adult dose 50 µg inhaled BD via DPI

Onset 15–20 minutes; duration 12 hours

PBS status ⚑ PBS Authority Required

💊

Formoterol

Oxis® Turbuhaler® · LABA

Adult dose 12 µg inhaled BD via DPI (6 µg BD may suffice in some patients)

Onset 1–3 minutes; duration 12 hours

PBS status ⚑ PBS Authority Required

💊

Indacaterol

Onbrez® Breezhaler® · LABA (ultra-LABA)

Adult dose 150 µg or 300 µg inhaled OD via capsule DPI

Duration 24 hours (once daily)

PBS status ⚑ PBS Authority Required

LAMA + LABA Fixed-Dose Combinations

💊

Tiotropium + Olodaterol

Spiolto® Respimat® · LAMA + LABA

Adult dose 2.5 µg + 2.5 µg (2 puffs) OD via Respimat

PBS status ⚑ PBS Authority Required

💊

Umeclidinium + Vilanterol

Anoro® Ellipta® · LAMA + LABA

Adult dose 62.5 µg + 25 µg inhaled OD via Ellipta DPI

PBS status ⚑ PBS Authority Required

Inhaled Corticosteroids (ICS) in COPD

🚨

ICS should NEVER be used as monotherapy in COPD. ICS monotherapy does not reduce mortality and increases pneumonia risk. ICS should only be added to LABA (and usually LAMA) in specific circumstances guided by eosinophil count and exacerbation history. Always reassess ICS benefit after 3–6 months and withdraw if no improvement.

When to add ICS:

Blood eosinophils ≥ 300 cells/µL AND ≥ 2 moderate exacerbations per year (or ≥ 1 hospitalised exacerbation) — strongest evidence
Blood eosinophils 100–299 cells/µL with ≥ 2 moderate exacerbations or ≥ 1 hospitalisation — consider
Blood eosinophils < 100 cells/µL — ICS unlikely to be beneficial; avoid
Patients with concomitant asthma–COPD overlap (ACO) — ICS should generally be continued

Triple Therapy: LAMA + LABA + ICS

💊

Fluticasone furoate + Umeclidinium + Vilanterol

Trelegy® Ellipta® · ICS + LAMA + LABA (Triple)

Adult dose 100 µg + 62.5 µg + 25 µg inhaled OD via Ellipta DPI (or 200 µg FF strength if indicated)

Indication Group E COPD with eosinophils ≥ 300, persistent exacerbations on LAMA + LABA

PBS status ⚑ PBS Authority Required

💊

Budesonide + Glycopyrronium + Formoterol

Breztri® Aerosphere® · ICS + LAMA + LABA (Triple)

Adult dose 320 µg + 14.4 µg + 10 µg (2 puffs) BD via pMDI

PBS status ⚑ PBS Authority Required

ICS Risks and De-escalation

⚠️

Pneumonia risk with ICS in COPD: All ICS-containing inhalers increase pneumonia risk in COPD (OR ~1.2–1.7). Risk is higher with fluticasone and in patients with FEV₁ < 50%, older age, lower BMI, and prior exacerbations. Use the lowest effective ICS dose. If a patient on ICS develops recurrent pneumonia, or has blood eosinophils < 100 cells/µL with no exacerbation benefit, wean and withdraw ICS (step-down: triple → LAMA + LABA → LAMA/LABA alone).

Roflumilast (Phosphodiesterase-4 Inhibitor)

💊

Roflumilast

Daxas® · PDE4 inhibitor

Adult dose 500 µg PO OD

Indication Severe COPD (FEV₁ < 50%) with chronic bronchitis phenotype, frequent exacerbations despite LAMA + LABA ± ICS

Renal adjustment No adjustment (not recommended if severe hepatic impairment — Child-Pugh C)

Cautions GI side effects (diarrhoea, nausea, weight loss), mood disturbances — avoid with depression history

PBS status ⚑ PBS Authority Required

Long-Term Oxygen Therapy & Pulmonary Rehabilitation

Long-Term Oxygen Therapy (LTOT)

LTOT is one of the few interventions in COPD that has been demonstrated to improve survival, but only when prescribed to the correct patients at adequate duration. It is indicated when the patient has chronic, stable hypoxaemia (not during an exacerbation — reassess at least 6–8 weeks after recovery).

Indications for LTOT

Criteria	Threshold	Evidence
Primary criteria	PaO₂ ≤ 55 mmHg (7.3 kPa) or SpO₂ ≤ 88%	NOTT and MRC trials — survival benefit with ≥ 15 h/day
Secondary criteria	PaO₂ 56–59 mmHg (7.4–7.8 kPa) WITH one of: cor pulmonale, polycythaemia (Hct > 55%), or pulmonary hypertension on echo	May still derive survival benefit
NOT indicated	SpO₂ 89–93% at rest without above features	LOTT trial — no benefit in this range

⚠️

LTOT must be prescribed ≥ 15 hours/day (including overnight) to achieve survival benefit. Survival benefit is proportional to hours of use. Short-burst oxygen for dyspnoea alone (without hypoxaemia) has no evidence of benefit and should not be prescribed.

Oxygen Delivery in Australia

Home oxygen concentrators: stationary units (typically 1–4 L/min via nasal cannulae); supplied through State/Territory Home Oxygen Program services (e.g., Ambulance Victoria, NSW Health, QLD Health)
Portable oxygen concentrators (POCs): for ambulatory use; some State programmes fund these; battery-powered, lighter weight
Cylinder oxygen: for backup/emergency; BOC / Air Liquide supply
Funding: LTOT is funded through State/Territory public health systems, not PBS. Eligibility confirmed by a respiratory specialist or physician after ABG/spirometry assessment
Electrical safety: home oxygen requires fire safety assessment (no smoking, clear 2 m from open flames, smoke alarms). Energy providers must be notified in some jurisdictions — priority restoration list.

Ambulatory/Exercise Oxygen

Patients who desaturate during exercise (SpO₂ < 88% during 6-minute walk test or equivalent) but do NOT meet resting LTOT criteria may benefit from ambulatory oxygen during exertion. Evidence is mixed; prescribe on a trial basis with functional outcome reassessment at 6–12 weeks.

Nocturnal Oxygen

Isolated nocturnal desaturation (SpO₂ < 88% for > 30% of sleep time) in the absence of daytime hypoxaemia — consider overnight oximetry or polysomnography. Ensure obstructive sleep apnoea is excluded (overlap syndrome). LTOT for isolated nocturnal desaturation without daytime criteria is not standard practice — specialist assessment recommended.

Pulmonary Rehabilitation (PR)

Pulmonary rehabilitation is a structured, evidence-based programme of supervised exercise training, education, and psychosocial support for people with chronic lung disease. It is one of the most effective interventions in COPD, reducing dyspnoea, improving exercise capacity and quality of life, and reducing hospital admissions and length of stay following exacerbations.

✅

Referral to pulmonary rehabilitation should be offered to ALL symptomatic COPD patients (GOLD B or E), including those who have recently been hospitalised for an exacerbation (post-exacerbation PR within 4 weeks of discharge is particularly beneficial). It should also be considered in GOLD A patients with activity limitation.

Programme Components

Component	Details
Duration	6–8 weeks (minimum 2 supervised sessions per week); some programmes extend to 12 weeks
Exercise training	Aerobic (walking, cycling) at 60–80% peak capacity; resistance/strength training for upper and lower limbs; flexibility
Education	Self-management of exacerbations, inhaler technique, breathing strategies (pursed-lip, pacing), nutritional advice, travel advice
Psychosocial	Anxiety and depression screening, peer support, goal setting, advance care planning discussions
Assessment tools	6-Minute Walk Test (6MWT), COPD Assessment Test (CAT), St George's Respiratory Questionnaire (SGRQ), mMRC dyspnoea scale

Access in Australia

Hospital outpatient programmes: most public hospitals offer PR; typically free through public system; requires referral
MBS item 93660: Medicare rebate for individual allied health services (exercise physiology, physiotherapy) under a Team Care Arrangement (TCA) — may supplement but not replace comprehensive PR
Tele-rehabilitation: emerging evidence supports home-based or tele-rehabilitation, especially important for rural/remote patients; some programmes available through Lung Foundation Australia
Wait times: average wait time for public PR programmes in Australia is 2–6 months; advocate for priority post-exacerbation access
Community maintenance: after completing a formal programme, patients should be encouraged to continue community-based exercise (Lung Foundation Australia's "Lung Moves" programmes, local exercise groups)

Acute Exacerbation Management (Brief Overview)

For completeness, key principles of acute COPD exacerbation management in general practice:

Oral prednisolone: 40–50 mg PO daily for 5 days (short course equivalent; no taper required) — reduces treatment failure and recovery time
Antibiotics when ≥ 2 of: increased dyspnoea, increased sputum volume, increased sputum purulence (Anthonisen criteria): amoxicillin 500 mg PO TDS for 5–7 days, or doxycycline 200 mg PO day 1 then 100 mg OD for 5 days, or amoxicillin-clavulanate 875/125 mg PO BD for 5–7 days
Short-acting bronchodilators: salbutamol 4–6 puffs via pMDI + spacer or nebulised salbutamol 2.5–5 mg PRN (up to QID) ± ipratropium 500 µg nebulised QID
Consider hospital admission if: severe dyspnoe despite treatment, respiratory rate > 25, SpO₂ < 90% on room air, altered mental status, failure to respond to initial treatment, significant comorbidities, unable to manage at home

Special Populations

🤰

Pregnancy

Salbutamol is safe in pregnancy (Category A). Continue PRN use.

Ipratropium — limited data but generally considered safe; use if needed.

LABA/LAMA: limited pregnancy data; tiotropium use individual risk-benefit; salmeterol has most pregnancy data among LABAs.

ICS: budesonide is preferred in pregnancy (most safety data — Category B/A in Australia).

Prednisolone: can be used for exacerbations if needed; short courses carry low teratogenic risk.

Uncontrolled COPD poses greater risk to pregnancy than medication. Continue appropriate therapy and involve respiratory/obstetric team early.

👶

Paediatrics

COPD is an adult disease; however, paediatric asthma with persistent airflow obstruction may mimic COPD. E-cigarette/vaping-related lung injury is an emerging differential in adolescents.

Alpha-1 antitrypsin deficiency should be considered in children/young adults with unexplained lung disease. Neonatal screening is available but not routine in Australia.

Paediatric drug doses: salbutamol 2.5 mg nebulised (or 2–4 puffs via spacer) < 6 years weight-based; no COPD-specific paediatric recommendations exist.

👴

Elderly (≥ 65 years)

Higher risk of over-diagnosis with fixed FEV₁/FVC < 0.70 (age-related decline). Use LLN where available.

Comorbidities: heart failure, osteoporosis, anxiety/depression, cognitive impairment, frailty — all impact COPD management and self-care ability.

Inhaler selection: consider dexterity, inspiratory flow, cognitive ability. pMDI + spacer is often best if DPI inspiratory flow is inadequate. Consider once-daily LAMA over BD regimens to improve adherence.

Anticholinergic burden: be mindful of cumulative anticholinergic load with LAMA + other medications (antihistamines, bladder antimuscarinics, TCAs).

Falls risk increases with COPD due to deconditioning, hypoxia, and medication effects. Pulmonary rehabilitation reduces falls risk.

🫘

Renal Impairment

Inhaled bronchodilators: generally no significant renal adjustment required for inhaled therapies; minimal systemic absorption.

Varenicline: reduce dose if eGFR < 30 mL/min (0.5 mg OD).

Bupropion: 150 mg OD if eGFR < 30 or on dialysis.

Oral prednisolone: no renal adjustment but increased risk of fluid retention and hyperglycaemia in CKD.

Patients on dialysis with COPD have very high morbidity. Ensure oxygen assessment is not confused with dialysis-related hypoxia.

🫁

Hepatic Impairment

Most inhaled COPD therapies require no hepatic dose adjustment.

Roflumilast: contraindicated in Child-Pugh C hepatic impairment; caution in Child-Pugh B.

Oral prednisolone: caution in cirrhosis (impaired metabolism, fluid retention, GI bleeding risk). Consider lower doses or shorter courses.

Hepatopulmonary syndrome should be considered if significant hypoxia in cirrhosis — different mechanism from COPD.

🛡️

Immunocompromised

ICS-related pneumonia risk is elevated in immunosuppressed patients; weigh benefit vs risk carefully.

Influenza vaccination annually (funded under NIP) and pneumococcal vaccination (23vPPV + 13vPCV as per NIP schedule) are especially important.

Nontuberculous mycobacteria (NTM): increased prevalence in COPD with ICS use; consider NTM culture if persistent productive cough or failure to improve on treatment.

COVID-19 vaccination (including boosters) is recommended for all COPD patients regardless of immunosuppression status.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Australians experience COPD at 2.5 times the rate of non-Indigenous Australians, with earlier onset, greater severity, and significantly higher mortality. COPD is the third leading cause of the health gap between Indigenous and non-Indigenous Australians. In some remote communities, non-smoking COPD attributable to biomass fuel exposure and childhood respiratory infections is a significant contributor.

Prevalence & Burden

Age-standardised prevalence ~2.5× non-Indigenous rates. COPD mortality is 2.5–3× higher. Earlier onset (from age 35+). Higher rates in remote and very remote areas (AIHW 2023).

Smoking Rates

Approximately 40% of Aboriginal and Torres Strait Islander adults smoke daily (vs ~10% non-Indigenous), though rates are declining. Tackling Indigenous Smoking (TIS) programme provides community-based support. Aboriginal and Torres Strait Islander-specific Quitline (13 7848 press 1).

Access to Spirometry

Limited spirometry availability in many remote and regional Aboriginal Community Controlled Health Organisations (ACCHOs). Point-of-care spirometry devices, training for Aboriginal Health Practitioners/Workers, and telehealth-supported interpretation can improve access. Optimal Care Pathway for COPD emphasises spirometry access equity.

Access to Pulmonary Rehabilitation

Very few PR programmes in rural/remote areas. Culturally safe programmes co-designed with communities, delivered by Aboriginal Health Workers, using yarning circles and incorporating Indigenous concepts of wellbeing, are most effective. Tele-rehabilitation and community-based models under development.

Inhaler Technique & Health Literacy

Higher rates of incorrect inhaler use. Visual teach-back tools, pictorial medication plans, and Aboriginal Health Worker support improve technique and adherence. Consider simplified regimens (once-daily LAMA vs BD regimens).

Environmental Exposures

Biomass fuel (woodfire heating/cooking) in remote communities, dust exposure, overcrowded housing increasing infection transmission. Advocacy for housing improvements, clean energy, and ventilation is a public health priority.

Home Oxygen Access

Electricity supply reliability in some remote communities affects concentrator use. Generator backup, portable oxygen cylinders, and priority energy restoration are essential. Fire safety education tailored to community living contexts.

Culturally Safe Care

Recognise the role of family and community in health decision-making. Use culturally appropriate communication (avoid medical jargon, use interpreters for language groups). Acknowledge the impact of intergenerational trauma, racism, and social determinants on respiratory health. Involve ACCHOs and Aboriginal Health Workers in all stages of care planning.

📋

Closing the Gap: COPD is a National Agreement target area under the National Agreement on Closing the Gap (Target 1 — life expectancy). Culturally safe spirometry access, proactive screening from age 35 in high-risk communities, funded smoking cessation programmes through ACCHOs, and community-based pulmonary rehabilitation are priority actions identified in the Lung Foundation Australia's COPD Optimal Care Pathway and AIHW reports.

Monitoring & Follow-Up

COPD is a chronic, progressive disease requiring ongoing monitoring. A structured GP Management Plan (GPMP, MBS item 721) and Team Care Arrangement (TCA, MBS item 723) are recommended for all COPD patients to coordinate care, access allied health services, and support self-management.

Monitoring Schedule

Every visit

Symptom assessment (mMRC, CAT score), inhaler technique check, smoking status, oxygen saturation, medication review, exacerbation history since last visit.

3–6 months

After initiation or change of therapy: assess response, side effects, adherence. Reassess ICS benefit if on triple therapy. Review blood eosinophils if not recently checked.

Annually

Spirometry (monitor FEV₁ trajectory — normal decline ~20–30 mL/year in COPD vs 10–20 mL/year normal); influenza vaccination; medication reconciliation; pulmonary rehabilitation review (repeat PR if not completed or new functional decline); ABG if SpO₂ ≤ 92%; chest X-ray if new or worsening symptoms; review oxygen status.

Post-exacerbation (2–4 weeks)

Reassess recovery, spirometry if not at baseline, consider PR referral, optimise pharmacotherapy, consider LTOT assessment if recovery incomplete, review self-management action plan.

Exacerbation Action Plan

Every COPD patient should have a written COPD Action Plan (similar to asthma action plans) developed collaboratively with their GP. The plan should include:

Recognition of worsening symptoms (increased dyspnoea, sputum volume/purulence)
Self-management steps (increase SABA, start standby prednisolone and/or antibiotics if previously agreed)
When to contact the GP or present to ED
Lung Foundation Australia provides a free downloadable COPD Action Plan template

📚 References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. GOLD; 2024. Available from: goldcopd.org.
2. Yang IA, Brown JL, George J, et al. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2024. Thoracic Society of Australia and New Zealand (TSANZ). Version 3.0. Lung Foundation Australia; 2024.
3. Australian Institute of Health and Welfare (AIHW). Chronic obstructive pulmonary disease (COPD). Cat. no. ACM 36. Canberra: AIHW; 2023.
4. Abramson MJ, Crockett AJ, Dabscheck E, et al. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Medical Journal of Australia. 2023;218(7):315–323.
5. Lung Foundation Australia. COPD Optimal Care Pathway. Milton, QLD: Lung Foundation Australia; 2022.
6. Smoking cessation pharmacotherapy: a narrative review of efficacy, safety and tolerability. Australian Prescriber. 2023;46(3):82–87.
7. National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. NICE guideline NG115. London: NICE; 2019 (updated 2024).
8. Long-Term Oxygen Treatment Trial Research Group. A randomized trial of long-term oxygen for COPD with moderate desaturation. New England Journal of Medicine. 2016;375(17):1617–1627.
9. Alison JA, McKeough ZJ, Johnston K, et al. Australian and New Zealand Pulmonary Rehabilitation Guidelines. Respirology. 2017;22(4):800–819.
10. Australian Government Department of Health and Aged Care. National Immunisation Program Schedule — pneumococcal and influenza recommendations. Canberra: DoH; 2024.
11. Liang J, Abramson MJ, Zwar N, et al. Diagnosing COPD and supporting smoking cessation in general practice: evidence-practice gaps. Medical Journal of Australia. 2018;208(6):263–266.
12. The LOTT Research Group. Long-term oxygen treatment trial (LOTT): results. Am J Respir Crit Care Med. 2016;194(4):A2486.
13. Australian Government Department of Health. Tackling Indigenous Smoking Programme. Canberra: DoH; 2024.

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).